SCHEMBL11245696

SCHEMBL11245696

O=C1CC(c2ccccc2)C(=S)N1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DDB1 Q16531 1/20 0.49
CRBN Q96SW2 1/20 0.49
CYP19A1 P11511 1/20 0.49
SIRT2 Q8IXJ6 1/20 0.44
ALDH1A1 P00352 5/20 0.44
TSHR P16473 3/20 0.44
HSD17B10 Q99714 2/20 0.44
SMN1; SMN2 Q16637 1/20 0.44
HTT P42858 1/20 0.43
MAPT P10636 2/20 0.42
LMNA P02545 1/20 0.42
PKM P14618 1/20 0.42
TP53 P04637 2/20 0.42
KDM4E B2RXH2 1/20 0.42
CFTR P13569 1/20 0.41
GOPC Q9HD26 1/20 0.41
KMT2A Q03164 1/20 0.41
NPC1 O15118 1/20 0.41
HPGD P15428 2/20 0.40
ALOX15 P16050 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1567424 0.84 DDB1 (0.67) DDB1CRBNCYP19A1SIRT2ALDH1A1
SCHEMBL8300066 0.84 DDB1 (0.67) DDB1CRBNCYP19A1SIRT2ALDH1A1
Methane SCHEMBL7953352 0.82 DDB1 (0.65) DDB1CRBNCYP19A1SIRT2ALDH1A1
SCHEMBL4971631 0.77 DDB1 (0.49) DDB1CRBNCYP19A1SIRT2ALDH1A1
Carbamic Acid SCHEMBL28839963 0.77 CYP19A1 (0.62) DDB1CRBNCYP19A1SIRT2ALDH1A1
SCHEMBL12698414 0.74 ALDH1A1 (0.58) DDB1CRBNSIRT2ALDH1A1TSHR
SCHEMBL7156373 0.74 ALDH1A1 (0.58) DDB1CRBNSIRT2ALDH1A1TSHR
SCHEMBL880376 0.74 ALDH1A1 (0.58) DDB1CRBNSIRT2ALDH1A1TSHR
SCHEMBL5386997 0.71 MAPT (0.59) DDB1CRBNALDH1A1TSHRHSD17B10
SCHEMBL4263409 0.70 LMNA (0.47) DDB1CRBNCYP19A1SIRT2ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-106922129-B Methods of conjugating polypeptides 免疫医疗有限责任公司 2024-02-20 CN disclosed
EP-3200829-B1 METHOD OF CONJUGATING A POLYPEPTIDE MEDIMMUNE LLC (US) 2023-12-06 EP disclosed
US-20220160882-A1 METHOD OF CONJUGATING A POLYPEPTIDE MEDIMMUNE, LLC 2022-05-26 US disclosed
EP-0005348-B1 CARBAPENEM DERIVATIVES, A PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM BEECHAM GROUP PLC (GB) 1982-09-22 EP disclosed
US-4278686-A ANTIBIOTICS BEECHAM GROUP LIMITED (GB) 1981-07-14 US disclosed
EP-0005348-A1 Carbapenem derivatives, a process for their preparation and pharmaceutical compositions containing them BEECHAM GROUP PLC (GB) 1979-11-14 EP disclosed
EP-0005349-A1 Alkylcarbapenems, their preparation, use in pharmaceutical compositions and intermediates BEECHAM GROUP PLC (GB) 1979-11-14 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220160882-A1 METHOD OF CONJUGATING A POLYPEPTIDE ZYX, QPCT, MRPL21 DDB1 2719/4885CRBN 1083/4885CYP19A1 1622/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.